All
FDA Approves Dosing Reduction of Tecvayli in Relapsed, Refractory Myeloma
February 21st 2024The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.
Tagrisso Plus Chemo Approved by FDA for EGFR-Mutated NSCLC
February 16th 2024The Food and Drug Administration has approved Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.